Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue from operations fell to ₹15,645.08 lakhs (vs ₹16,407.21 lakhs in FY24), a decline of about 4.6%. Standalone profit after tax dropped sharply to ₹1,827.11 lakhs (vs ₹2,366.32 lakhs), down roughly 23%, with EPS at ₹22.11 versus ₹28.64. On a consolidated basis, PAT was ₹2,153.16 lakhs (vs ₹2,485.30 lakhs) with EPS of ₹26.06. The board recommended a dividend of ₹2 per share (face value ₹10) for FY25, subject to shareholder approval. Statutory auditors issued an unmodified (clean) opinion on the results. The board also appointed a new Secretarial Auditor (5-year term), Cost Auditor (FY26), Internal Auditor (2-year term), and Scrutinizer for the upcoming AGM.
Despite a clean audit and declared dividend, shareholders should note the year-on-year decline in both revenue and profits, with PAT falling nearly 23%. This signals margin pressure and weaker operating performance, though the company remains profitable with healthy reserves and positive operating cash flow.